Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).

Shares of Theravance Biopharma rapidly declined after the company announced a Phase III cardiac drug failed to meet the study’s primary endpoint and a significant shift in its R&D efforts that resulted in a 75 percent staff termination.